Switch theme
Sign up to access all valuation multiples
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company’s focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.
2006
65
LTM Revenue $91.7M
Last FY EBITDA -$19.0M
$845M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Cormedix has a last 12-month revenue (LTM) of $91.7M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Cormedix achieved revenue of $43.5M and an EBITDA of -$19.0M.
Cormedix expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Cormedix valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $91.7M | XXX | $43.5M | XXX | XXX | XXX |
| Gross Profit | $84.2M | XXX | $40.3M | XXX | XXX | XXX |
| Gross Margin | 92% | XXX | 93% | XXX | XXX | XXX |
| EBITDA | n/a | XXX | -$19.0M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -44% | XXX | XXX | XXX |
| EBIT | $15.7M | XXX | -$22.4M | XXX | XXX | XXX |
| EBIT Margin | 17% | XXX | -51% | XXX | XXX | XXX |
| Net Profit | $17.1M | XXX | -$17.9M | XXX | XXX | XXX |
| Net Margin | 19% | XXX | -41% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of June 23, 2025, Cormedix's stock price is $14.
Cormedix has current market cap of $922M, and EV of $845M.
See Cormedix trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $845M | $922M | XXX | XXX | XXX | XXX | $0.22 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of June 23, 2025, Cormedix has market cap of $922M and EV of $845M.
Cormedix's trades at 19.4x EV/Revenue multiple, and -44.5x EV/EBITDA.
Equity research analysts estimate Cormedix's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Cormedix has a P/E ratio of 53.8x.
See valuation multiples for Cormedix and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $922M | XXX | $922M | XXX | XXX | XXX |
| EV (current) | $845M | XXX | $845M | XXX | XXX | XXX |
| EV/Revenue | 9.2x | XXX | 19.4x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -44.5x | XXX | XXX | XXX |
| EV/EBIT | 53.7x | XXX | -37.8x | XXX | XXX | XXX |
| EV/Gross Profit | 10.0x | XXX | n/a | XXX | XXX | XXX |
| P/E | 53.8x | XXX | -51.4x | XXX | XXX | XXX |
| EV/FCF | 53.5x | XXX | -16.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialCormedix's last 12 month revenue growth is 93%
Cormedix's revenue per employee in the last FY averaged $0.7M, while opex per employee averaged $1.0M for the same period.
Cormedix's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Cormedix's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Cormedix and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 93% | XXX | 121% | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -44% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | 50% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.7M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.0M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 66% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 9% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 144% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Cormedix acquired XXX companies to date.
Last acquisition by Cormedix was XXXXXXXX, XXXXX XXXXX XXXXXX . Cormedix acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Cormedix founded? | Cormedix was founded in 2006. |
| Where is Cormedix headquartered? | Cormedix is headquartered in United States of America. |
| How many employees does Cormedix have? | As of today, Cormedix has 65 employees. |
| Who is the CEO of Cormedix? | Cormedix's CEO is Mr. Joseph Todisco. |
| Is Cormedix publicy listed? | Yes, Cormedix is a public company listed on NAS. |
| What is the stock symbol of Cormedix? | Cormedix trades under CRMD ticker. |
| When did Cormedix go public? | Cormedix went public in 2010. |
| Who are competitors of Cormedix? | Similar companies to Cormedix include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Cormedix? | Cormedix's current market cap is $922M |
| What is the current revenue of Cormedix? | Cormedix's last 12 months revenue is $91.7M. |
| What is the current revenue growth of Cormedix? | Cormedix revenue growth (NTM/LTM) is 93%. |
| What is the current EV/Revenue multiple of Cormedix? | Current revenue multiple of Cormedix is 9.2x. |
| Is Cormedix profitable? | Yes, Cormedix is EBITDA-positive (as of the last 12 months). |
| What is the current FCF of Cormedix? | Cormedix's last 12 months FCF is $15.8M. |
| What is Cormedix's FCF margin? | Cormedix's last 12 months FCF margin is 17%. |
| What is the current EV/FCF multiple of Cormedix? | Current FCF multiple of Cormedix is 53.5x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
